Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Managed Care

• Publication date

  2003-12-01

• Fields of study

  Medicine, Economics

• Identifiers
  PMID 14712755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada

  2012cited by this paper
• Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland

  2012cited by this paper
• Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

  2002cited by this paper
• Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO.

  2002cited by this paper
• Modeling for health care and other policy decisions: uses, roles, and validity.

  2002cited by this paper
• Pharmacy Benefit Management

  2002cited by this paper
• Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis.

  2002cited by this paper
• Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.

  2002cited by this paper
• Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

  2001cited by this paper
• The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis.

  2001cited by this paper
• Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

  2001cited by this paper
• Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom

  2001cited by this paper
• Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.

  2001cited by this paper
• The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.

  2000cited by this paper
• Testing the Validity of Cost-Effectiveness Models

  2000cited by this paper
• Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.

  2000cited by this paper
• Pharmacoeconomic analyses: making them transparent, making them credible.

  2000cited by this paper
• Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.

  2000cited by this paper
• Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

  1999cited by this paper
• A guideline for the treatment and prevention of NSAID-induced ulcers

  1998cited by this paper
• Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.

  1998cited by this paper
• Recent considerations in nonsteroidal anti-inflammatory drug gastropathy.

  1998cited by this paper
• The use of claims databases for outcomes research: rationale, challenges, and strategies.

  1997cited by this paper
• The Use of Consensus Methods and Expert Panels in Pharmacoeconomic Studies

  1997cited by this paper
• Comparison of medical records and prescription claims files in documenting prescription medication therapy

  1996cited by this paper
• Experimental models of development, function, and neoplasia.

  1996cited by this paper
• The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec.

  1995cited by this paper
• Guidelines for the medical management of osteoarthritis, Part I. Osteoarthritis of the hip

  1995cited by this paper
• Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology.

  1995cited by this paper
• Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology.

  1995cited by this paper
• The journal's policy on cost-effectiveness analyses.

  1994cited by this paper

• TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility

  2019cites this paper
• Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data

  2018cites this paper
• Prescribing Promotional Targeted Drugs: The Explanatory Phenomena (Part II: A Qualitative Study)(การสั่งจ่ายยาที่มีการมุ่งส่งเสริมการขาย: การอธิบายปรากฎการณ์ที่เกิดขึ้น(ตอนที่ 2 – การศึกษาวิจัยเชิงคุณภาพ))

  2014cites this paper
• Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients

  2012cites this paper
• Computer Aided Infectious Disease Epidemiology - Bridging to Public Healt

  2010cites this paper
• Formulary Management in the Department of Defense

  2009cites this paper
• It's Only a Pharmacoeconomic Model--Believe It or Not

  2008cites this paper
• Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?

  2006cites this paper
• Oral fixed drug combination analgesic tramadol/paracetamol: benefits for patients and budgets

  2006cites this paper
• Economic Evaluation of Tramadol/ Paracetamol Combination Tablets for Osteoarthritis Pain in The Netherlands

  2005cites this paper
• Gastrointestinal Bleeding Rates Among Managed Care Patients Newly Started on COX-2 Inhibitors or Nonselective NSAIDs

  2005cites this paper
• Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.

  2005cites this paper
• Shopping for Drugs: 2004

  2004cites this paper
• Taking stock at 2 years--continuing the journey.

  2004cites this paper
• Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).

  2004cites this paper
• Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients.

  2004cites this paper